Abstract
Important advances have been made within in past few years in the treatment of glioma, however, the longterm prognosis after resection of glioma remains unsatisfactory as a result of a high incidence of recurrence. To solve this problem, many biologic therapies have been investigated. In the present study, we report a nanoparticle with properties for dual targeting of tumor cells and the neovasculature. The nanoparticle comprises encoding vasohibin and RGD 12-mer cationic peptide RKKRRQRRRRGD (Tat49-57RGD) peptides, which a nuclear nanoparticle within an extranuclear peptide envelope. Our results demonstrate that the nanoparticle could prevent tumor angiogenesis and inhibit tumor growth via attenuating neovasculature formation and inducing tumor apoptosis. Therefore, the dual targeting strategy of tumor cells and neovasculature represents an integrative approach in glioma therapy. This can be extended to additional agents to target multiple signal pathways or distinct tumor compartments.
Keywords: Dual targeting, U251 cells, vasohibin, RGD peptides, glioma, long-term prognosis , cationic peptide , tumor compartments, Traditional biologic , tumor vasculatures , therapeutical strategy , vasohibin plasmid , vasohibin , fetal bovine serum
Current Neurovascular Research
Title:Dual Targeting of Glioma U251 Cells with Nanoparticles Prevents Tumor Angiogenesis and Inhibits Tumor Growth
Volume: 9 Issue: 2
Author(s): Hongjie Chen, Kaichun Fan, Shousen Wang, Zheng Liu and Zhaocong Zheng
Affiliation:
Keywords: Dual targeting, U251 cells, vasohibin, RGD peptides, glioma, long-term prognosis , cationic peptide , tumor compartments, Traditional biologic , tumor vasculatures , therapeutical strategy , vasohibin plasmid , vasohibin , fetal bovine serum
Abstract: Important advances have been made within in past few years in the treatment of glioma, however, the longterm prognosis after resection of glioma remains unsatisfactory as a result of a high incidence of recurrence. To solve this problem, many biologic therapies have been investigated. In the present study, we report a nanoparticle with properties for dual targeting of tumor cells and the neovasculature. The nanoparticle comprises encoding vasohibin and RGD 12-mer cationic peptide RKKRRQRRRRGD (Tat49-57RGD) peptides, which a nuclear nanoparticle within an extranuclear peptide envelope. Our results demonstrate that the nanoparticle could prevent tumor angiogenesis and inhibit tumor growth via attenuating neovasculature formation and inducing tumor apoptosis. Therefore, the dual targeting strategy of tumor cells and neovasculature represents an integrative approach in glioma therapy. This can be extended to additional agents to target multiple signal pathways or distinct tumor compartments.
Export Options
About this article
Cite this article as:
Chen Hongjie, Fan Kaichun, Wang Shousen, Liu Zheng and Zheng Zhaocong, Dual Targeting of Glioma U251 Cells with Nanoparticles Prevents Tumor Angiogenesis and Inhibits Tumor Growth, Current Neurovascular Research 2012; 9 (2) . https://dx.doi.org/10.2174/156720212800410902
DOI https://dx.doi.org/10.2174/156720212800410902 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regulation of Hypoxia-inducible Factor-1α and Vascular Endothelial Growth Factor Signaling by Plant Flavonoids
Mini-Reviews in Medicinal Chemistry High Throughput Screening for Drug Discovery of Autophagy Modulators
Combinatorial Chemistry & High Throughput Screening The Arrestin Fold: Variations on a Theme
Current Genomics The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases
Anti-Infective Agents in Medicinal Chemistry Surface Plasmon Resonance Imaging Sensor for Cathepsin Determination Based on Immobilized Cystatin
Protein & Peptide Letters Insulin-Like Growth Factor 2 - The Oncogene and its Accomplices
Current Pharmaceutical Design Mesenchymal Cells in the Treatment of Spinal Cord Injury: Current & Future Perspectives
Current Stem Cell Research & Therapy Recent Nanocarrier Approaches for Targeted Drug Delivery in Cancer Therapy
Current Molecular Pharmacology Polymer-Based Drug Delivery Devices for Neurological Disorders
CNS & Neurological Disorders - Drug Targets Glutamate Receptor Agonists: Stereochemical Aspects
Current Topics in Medicinal Chemistry Cyclization in Opioid Peptides
Current Drug Targets FDG-PET/CT and SPECT/CT in Oncology
Current Medical Imaging Recent Advances in Transcranial Focused Ultrasound (FUS) Triggered Brain Delivery
Current Drug Targets Will Antiangiogenic Agents be a Future for Mesothelioma Therapy?
Current Medicinal Chemistry Risk Assessment of the Use of Autonomous Parvovirus-Based Vectors
Current Gene Therapy Cyclophilin A as a Target of Cisplatin Chemosensitizers
Current Cancer Drug Targets Thiazolidinedione: A Privileged Scaffold for the Development of Anticancer Agents
Current Topics in Medicinal Chemistry Small Molecular Inhibitors of p-STAT3: Novel Agents for Treatment of Primary and Metastatic CNS Cancers
Recent Patents on CNS Drug Discovery (Discontinued) MicroRNAs in Neuroblastoma: Biomarkers with Therapeutic Potential
Current Medicinal Chemistry Altering the Tropism of Lentiviral Vectors through Pseudotyping
Current Gene Therapy